166 related articles for article (PubMed ID: 26426164)
1. Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use.
Michallet M; Losem C
Acta Haematol; 2016; 135(1):44-52. PubMed ID: 26426164
[TBL] [Abstract][Full Text] [Related]
2. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
4. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
Covic A; Abraham I
Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
[TBL] [Abstract][Full Text] [Related]
5. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar ESAs: a comparative review.
Wilson P; Wood C
J Ren Care; 2015 Mar; 41(1):53-61. PubMed ID: 25348203
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
Dingermann T; Scotte F
Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
[TBL] [Abstract][Full Text] [Related]
8. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C
Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617
[TBL] [Abstract][Full Text] [Related]
9. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.
Michallet M; Luporsi E; Soubeyran P; Amar NA; Boulanger V; Carreiro M; Dourthe LM; Labourey JL; Lepille D; Maloisel F; Mouysset JL; Nahon S; Narciso B; Nouyrigat P; Radji R; Sakek N; Albrand H;
BMC Cancer; 2014 Jul; 14():503. PubMed ID: 25011615
[TBL] [Abstract][Full Text] [Related]
10. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
11. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
[TBL] [Abstract][Full Text] [Related]
12. A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors.
Alifieris CE; Orfanakos K; Papanota A; Stathopoulos GP; Sitaras N; Trafalis DT
J Cancer Res Clin Oncol; 2017 Apr; 143(4):717-725. PubMed ID: 28078434
[TBL] [Abstract][Full Text] [Related]
13. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
14. Clinical safety of biosimilar recombinant human erythropoietins.
Abraham I; MacDonald K
Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.
Tzekova V; Mihaylov G; Elezovic I; Koytchev R;
Curr Med Res Opin; 2009 Jul; 25(7):1689-97. PubMed ID: 19505200
[TBL] [Abstract][Full Text] [Related]
17. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
[TBL] [Abstract][Full Text] [Related]
18. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
Agarwal AB; McBride A
Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.
Gascón P; Goldsmith D; Aapro M; Dellanna F; Esmael A; Zabransky M
Crit Rev Oncol Hematol; 2023 Jan; 181():103894. PubMed ID: 36481307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
